Logo image of PVLA

PALVELLA THERAPEUTICS INC (PVLA) Stock Fundamental Analysis

NASDAQ:PVLA - Nasdaq - US6979471090 - Common Stock - Currency: USD

24.13  -0.65 (-2.62%)

After market: 24.13 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PVLA. PVLA was compared to 558 industry peers in the Biotechnology industry. While PVLA has a great health rating, there are worries on its profitability. PVLA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PVLA had negative earnings in the past year.
In the past year PVLA has reported a negative cash flow from operations.
PVLA had negative earnings in each of the past 5 years.
In the past 5 years PVLA always reported negative operating cash flow.
PVLA Yearly Net Income VS EBIT VS OCF VS FCFPVLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

PVLA has a better Return On Assets (-19.76%) than 78.39% of its industry peers.
With a decent Return On Equity value of -27.85%, PVLA is doing good in the industry, outperforming 80.00% of the companies in the same industry.
Industry RankSector Rank
ROA -19.76%
ROE -27.85%
ROIC N/A
ROA(3y)-42.7%
ROA(5y)-36.72%
ROE(3y)-100.33%
ROE(5y)-95.22%
ROIC(3y)N/A
ROIC(5y)N/A
PVLA Yearly ROA, ROE, ROICPVLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

PVLA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PVLA Yearly Profit, Operating, Gross MarginsPVLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

More info and screens

8

2. Health

2.1 Basic Checks

PVLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PVLA has more shares outstanding
The number of shares outstanding for PVLA has been increased compared to 5 years ago.
PVLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PVLA Yearly Shares OutstandingPVLA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PVLA Yearly Total Debt VS Total AssetsPVLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 5.27 indicates that PVLA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.27, PVLA belongs to the best of the industry, outperforming 80.36% of the companies in the same industry.
There is no outstanding debt for PVLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.27
ROIC/WACCN/A
WACC9.47%
PVLA Yearly LT Debt VS Equity VS FCFPVLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

PVLA has a Current Ratio of 7.33. This indicates that PVLA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PVLA (7.33) is better than 67.14% of its industry peers.
PVLA has a Quick Ratio of 7.33. This indicates that PVLA is financially healthy and has no problem in meeting its short term obligations.
PVLA has a Quick ratio of 7.33. This is in the better half of the industry: PVLA outperforms 67.50% of its industry peers.
Industry RankSector Rank
Current Ratio 7.33
Quick Ratio 7.33
PVLA Yearly Current Assets VS Current LiabilitesPVLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

PVLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.99%, which is quite impressive.
The Revenue for PVLA has decreased by -17.56% in the past year. This is quite bad
PVLA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.49% yearly.
EPS 1Y (TTM)34.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-17.56%
Revenue growth 3Y-17.59%
Revenue growth 5Y0.49%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, PVLA will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.92% on average per year.
The Revenue is expected to decrease by -26.21% on average over the next years. This is quite bad
EPS Next Y99.01%
EPS Next 2Y38.38%
EPS Next 3Y23.35%
EPS Next 5Y12.92%
Revenue Next Year20.37%
Revenue Next 2Y-97.65%
Revenue Next 3Y-25.99%
Revenue Next 5Y-26.21%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PVLA Yearly Revenue VS EstimatesPVLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2027 10M 20M 30M 40M
PVLA Yearly EPS VS EstimatesPVLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PVLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PVLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PVLA Price Earnings VS Forward Price EarningsPVLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PVLA Per share dataPVLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as PVLA's earnings are expected to grow with 23.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.38%
EPS Next 3Y23.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PVLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALVELLA THERAPEUTICS INC

NASDAQ:PVLA (5/30/2025, 8:00:00 PM)

After market: 24.13 0 (0%)

24.13

-0.65 (-2.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners27.73%
Inst Owner Change27.05%
Ins Owners17.49%
Ins Owner Change105.3%
Market Cap266.88M
Analysts82.67
Price Target50.32 (108.54%)
Short Float %3.15%
Short Ratio2.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)32.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-40.84%
EPS NY rev (1m)0%
EPS NY rev (3m)18.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-57.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5035.43
P/FCF N/A
P/OCF N/A
P/B 4.26
P/tB 4.26
EV/EBITDA N/A
EPS(TTM)-36
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-4.88
FCFYN/A
OCF(TTM)-4.87
OCFYN/A
SpS0
BVpS5.66
TBVpS5.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.76%
ROE -27.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.7%
ROA(5y)-36.72%
ROE(3y)-100.33%
ROE(5y)-95.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.98%
Cap/Sales 322.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.33
Quick Ratio 7.33
Altman-Z 5.27
F-Score3
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)28.39%
Cap/Depr(5y)118.53%
Cap/Sales(3y)2.48%
Cap/Sales(5y)4.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y99.01%
EPS Next 2Y38.38%
EPS Next 3Y23.35%
EPS Next 5Y12.92%
Revenue 1Y (TTM)-17.56%
Revenue growth 3Y-17.59%
Revenue growth 5Y0.49%
Sales Q2Q%-100%
Revenue Next Year20.37%
Revenue Next 2Y-97.65%
Revenue Next 3Y-25.99%
Revenue Next 5Y-26.21%
EBIT growth 1Y11.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.9%
EBIT Next 3Y-6.3%
EBIT Next 5Y-21.87%
FCF growth 1Y11.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.2%
OCF growth 3YN/A
OCF growth 5YN/A